BTIG Research Reaffirms “Neutral” Rating for Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health (NYSE:HIMS)‘s stock had its “neutral” rating restated by investment analysts at BTIG Research in a research note issued to investors on Tuesday,Benzinga reports.

HIMS has been the subject of a number of other research reports. JPMorgan Chase & Co. began coverage on Hims & Hers Health in a report on Friday, April 24th. They set an “overweight” rating and a $35.00 target price for the company. Barclays boosted their price target on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday. TD Cowen dropped their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research note on Friday, March 27th. Finally, Evercore set a $24.00 price target on Hims & Hers Health in a research note on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $32.21.

Hims & Hers Health Stock Up 3.0%

HIMS opened at $29.12 on Tuesday. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The company has a market capitalization of $6.64 billion, a P/E ratio of 57.10, a P/E/G ratio of 3.85 and a beta of 2.43. The stock has a fifty day moving average of $23.08 and a 200-day moving average of $29.44.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same period in the prior year, the business posted $0.20 EPS. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, equities analysts expect that Hims & Hers Health will post 0.53 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the transaction, the insider owned 299,368 shares in the company, valued at $8,981,040. The trade was a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 204,857 shares of company stock worth $5,285,706 in the last ninety days. 13.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Pathway Capital Management LP acquired a new position in Hims & Hers Health during the third quarter worth about $6,766,000. Steadview Capital Management LLC raised its stake in Hims & Hers Health by 80.0% during the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock worth $39,809,000 after acquiring an additional 311,845 shares in the last quarter. Farallon Capital Management LLC raised its stake in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. BIT Capital GmbH raised its stake in Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after acquiring an additional 938,728 shares in the last quarter. Finally, State of Michigan Retirement System raised its stake in Hims & Hers Health by 49.2% during the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after acquiring an additional 678,600 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Management raised 2026 revenue guidance, signaling confidence that demand for personalized care remains strong. Hims & Hers raises 2026 revenue forecast on strong demand for personalized care
• Positive Sentiment: The company highlighted new care offerings and expansion of its digital healthcare platform, including labs, menopause and testosterone care, plus a Novo Nordisk GLP-1 partnership. Hims & Hers Expands Digital Healthcare Platform via New Care Offerings

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.